TFX Teleflex Incorporated

BSX's MedSurg segment supports growth, with Endoscopy and Neuromodulation gains offsetting Urology challenges and portfolio gaps.

Check out the companies making headlines yesterday:

Teleflex (TFX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Recently, Teleflex attracted attention as investors reacted to commentary that, despite weak constant-currency revenue growth and declining earnings metrics, some see the company as lagging broader market performance while others highlight its potential. What stands out is that new leadership and an emphasis on reducing debt are being framed as possible catalysts for a meaningful re-rating story in the eyes of investment firms. Next, we’ll examine how Teleflex’s new leadership focus and...

Shares of medical technology company Teleflex (NYSE:TFX) jumped 4.5% in the afternoon session after BofA Securities upgraded the stock from Neutral to Buy and raised its price target.

Even though Teleflex (currently trading at $122.08 per share) has gained 6.2% over the last six months, it has lagged the S&P 500’s 21.4% return during that period. This may have investors wondering how to approach the situation.

Teleflex (TFX) could be the next re-rating story, with its growth prospects, new leadership and pote

Roblox downgraded, Royal Caribbean upgraded: Wall Street's top analyst calls

Wall Street analysts are making bold moves as the third quarter closes, with major calls hitting PepsiCo, Roblox, Snowflake, and a Bitcoin infrastructure stock carrying a price target that will turn heads.

QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.

ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.

BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.

IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.

Quest Diagnostics gains momentum from customer wins, advanced diagnostics and AI initiatives, while reimbursement uncertainty, costs and debt pose challenges.

Teleflex board refresh puts governance in focus Teleflex (TFX) has added veteran medical device executive Sean M. Salmon to its Board of Directors. This appointment gives investors a fresh angle on the company’s governance and its long term direction. Teleflex shares have eased in the short term, with the 7 day share price return down 4.94% and the 30 day share price return down 10.31%. The 90 day share price return of 2.34% and 1 year total shareholder return of 2.67% point to only modest...

IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.

PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.

National Vision's premium-product demand and stronger customer mix support growth, but rising costs and vendor dependence remain key risks for investors.

RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.

TFX, CNC, ENS, ROCK and FAF stand out among five low P/B stocks offering attractive value and promising growth prospects.

Align Technology expands Invisalign and digital dentistry adoption as iTero gains traction, but weak capital spending and currency volatility remain risks.

TFX vs. PEN: Which Stock Is the Better Value Option?

NEOG advances product innovation and recovers Animal Safety operations, but high debt and intense competition remain key risks.

Looking back on surgical equipment & consumables - specialty stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Teleflex (NYSE:TFX) and its peers.

Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.

On August 6, Teleflex Incorporated (NYSE:TFX) reported second-quarter results for the period ended June 30, and the numbers told two different stories at once. Revenue from continuing operations climbed to $570.3 million, up 28.9% from a year earlier, while GAAP diluted earnings per share slid to $0.96 from $1.54. Add in a completed divestiture, a […]

MDT beats Q1 earnings and revenue estimates as broad-based growth drives shares higher and prompts a fiscal 2027 guidance boost.

Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.

Teleflex stock has delivered a sharp decline for long term holders over the past five years, yet today the intrinsic value estimate points to a discount while market based multiples suggest the shares are not cheap. That split, combined with the stock’s recent rebound, puts the current Teleflex valuation under closer scrutiny for investors trying to decide what the market is really pricing in. Teleflex has fallen about 63.6% over five years, which means recent gains still sit against a deep...

ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.

TFX's Vascular growth, Interventional expansion and improved leverage support its outlook, while currency volatility remains a key risk.

MDT's Cardiovascular gains and renal denervation growth offer upside, but tariffs and currency headwinds cloud its outlook.

TFX vs. PEN: Which Stock Is the Better Value Option?

VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.

Valuation is improving for Teleflex, but slower Vascular Intervention integration and margin pressure keep execution risks in focus.

LH's specialty-testing expansion, strategic partnerships and buybacks support growth, while reimbursement and cost pressures pose risks.

TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.

Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.

IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.

CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.

EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.

ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Phibro Animal Health's Animal Health growth and global reach support its outlook, but Brazil's antimicrobial transition and trade risks cloud near-term prospects.

Teleflex’s second quarter was marked by revenue and non-GAAP earnings per share above Wall Street expectations, yet the operating margin declined significantly year over year. Management attributed the quarter’s results primarily to strong execution in its Vascular and Surgical businesses, as well as accelerated progress on its strategic transformation plan. CEO Jason Weidman cited robust demand for hemostatic and ligation products but acknowledged that performance in the Interventional segment

In early August 2026, Teleflex Incorporated reported second-quarter results showing higher sales of US$570.33 million but lower net income of US$99.69 million year-on-year, cut its 2026 earnings guidance, completed a US$250 million repurchase of 1,900,000 shares, and affirmed a quarterly US$0.34 dividend payable on September 30, 2026. The mix of revenue growth alongside weaker earnings, extended integration timelines for the Vascular Intervention acquisition, and active balance sheet...

Teleflex stock has rebounded in the short term yet still sits far below its level of five years ago, while the valuation checks send mixed signals as a Discounted Cash Flow (DCF) estimate points to upside and market multiples lean the other way. Over the past 5 years, Teleflex shares have declined 62.1%, which puts the current valuation in the context of a long and painful reset for investors. Completion of the US$1.5b OEM business sale and planned debt reduction and buybacks can support the...

CEO Weidman discusses integration delays, FDA approvals, and capital allocation strategy.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

TFX vs. PEN: Which Stock Is the Better Value Option?